Cellectar Biosciences Inc., of Madison, Wis., said the FDA's Office of Orphan Products Development granted orphan drug designation to CLR-131, its lead phospholipid drug conjugate (PDC) product candidate, for the treatment of neuroblastoma, a rare pediatric cancer.